Long-term (40 months) adjuvant therapy with octreotide LAR has been shown to reduce GH and IGF-1 levels, and reduce tumor volume, in patients with persistent and poorly controlled acromegaly after transsphenoidal surgery, adjuvant radiation, and/or dopamine agonists, but without prior treatment with somatostatin analogues [41]. This evidence concerns the gene IGF1 and neoplasm.